Can I read Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C on EtoBox?

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C by Fred Poordad; Eric Lawitz; Mitchell L. Shiffman; Tarek Hassanein; Andrew J. Muir; Bruce R. Bacon; Jamie Heise; Deanine Halliman; Eric Chun; Janet Hammond is a Medicine article available to read on EtoBox.

What is Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C about?

Muir is a consultant for, is on the speakers' bureau of, and received grants from Merck. He received grants from Valeant. He is also a consultant for and received grants from Zynogenetics. Dr. Poordad is a consultant for and received grants from Valeant. Dr. Shiffman advises and received grants from Biolex, Conatus, Human Genome Sciences, Romark, Valeant, Vertex, and Zymogenetics. He also advises Anadys, Bristol-Myers Squibb, and Novartis. He received grants from GlaxoSmithKline, Globeimmune, Idenix, Johnson & Johnson, and Wyeth. He is a consultant for Pfizer. He is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. He advises, is on the speakers' bureau of, and received grants from Schering-Plough.

Who reads Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C?

Author

Fred Poordad; Eric Lawitz; Mitchell L. Shiffman; Tarek Hassanein; Andrew J. Muir; Bruce R. Bacon; Jamie Heise; Deanine Halliman; Eric Chun; Janet Hammond

Publisher

Ovid Technologies (Wolters Kluwer Health)

Published

2010

Language

EN

Field

Medicine (Health Sciences)